Intermittent versus continuous chemotherapy in advanced colorectal cancer: A randomised 'GISCAD' trial

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1236-1242

  Labianca, R ^a   Sobrero, A ^b   Isa, L ^c   Cortesi, E ^d   Barni, S ^e   Nicolella, D ^f   Aglietta, M ^g   Lonardi, S ^h   Corsi, D ⁱ   Turci, D ^j   Beretta, G D ^a   Fornarini, G ^b   Dapretto, E ^k   Floriani, I ^l   Zaniboni, A ^m  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Serbelloni Hospital   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

^e TREVIGLIO HOSPITAL   (Italy)

^f S G MOSCATI HOSPITAL   (Italy)

^g CANDIOLO CANCER INSTITUTE   (Italy)

^h VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

ⁱ FATEBENEFRATELLI HOSPITAL   (Italy)

^j Oncologia e Ematologia   (Italy)

^k SAN GERARDO HOSPITAL   (Italy)

^l MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^m Oncologia Medica   (Italy)

more..

Author keywords

FOLFIRI; Intermittent chemotherapy; Metastatic colorectal cancer

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INTERMITTENT THERAPY; FEMALE; FEVER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL;

EID: 79955506636     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq580     Document Type: Article

References (24)

1. Schmoll HJ, Buechele T, Grothey A et al. Where do we stand with 5fluorouracil? Semin Oncol 1999; 26: 589-605.
2. Sobrero A, Herrmann R, Rischin D et al. Does biomodulation of 5fluorouracil improve results? Eur J Cancer 1999; 35: 186-194.
3. Vincent M, Labianca R, Harper P. Which 5fluorouracil regimen? The great debate. Anticancer Drugs 1999; 10: 337-354.
4. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
5. Tournigand C, Andrè T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 2004; 22: 229-237.
6. Colucci G, Gebbia V, Paoletti G et al. Phase III randomised trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875.
7. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
8. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
9. Chu E. The role of a drug holiday: even patients with cancer need a vacation. Clin Colorectal Cancer 2006; 6(3): 182.
10. Beers Gibson T, Grothey A. Do all patients with metastatic colorectal cancer need chemotherapy until disease progression? Clin Colorectal Cancer 2006; 6: 196-201.
11. Maughan TS, James RD, Kerr DJ et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361: 457-464.
12. Tournigand C, Cervantes A, Figer A et al. OPTIMOX 1: a randomised study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24: 394-400.
13. Allegra C, Blanke C, Buyse M et al. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007; 25: 3572-3575.
14. Saltz L. Planned treatment interruptions and chemotherapy-free intervals in the treatment of metastatic colorectal cancer: time to start stopping? Semin Oncol 2006; 33 (Suppl 11): 28-32.
15. Sobrero A, Tempestini A, Pedemonte S et al. Intermittent FU treatment for colorectal cancer Proceedings of Paris Symposium on Cancer Chemotherapy, Paris, France, February 2000.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1961; 53: 457-481.
17. Peto R. Asymptotically efficient RANK invariant test procedures. J R Stat Soc A 1986; 135(2): 185-207.
18. Marubini E, Valsecchi MG. Analyzing Survival Data from Clinical Trials and Observational Studies. Boston, MA: John Wiley and Sons 1997.
19. Mandalà M, Barni S, Floriani I et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCADalternating schedule' study findings. Eur J Cancer 2009; 45(1): 65-73.
20. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214.
21. Chibaudel B, Maindrault-Goebel F, Lledo G et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 2009; 27: 5727-5733.
22. Hochster HS. Stop and go: yes or no? J Clin Oncol 2009; 27: 5677-5679.
23. Lai R, Dickson J, Cunningham D et al. A randomised trial comparing definedduration with continuous irinotecan until disease progression in fluoropyrimidine and thymidilate synthase inhibitor-resistant advanced colorectal cancer. J Clin Oncol 2004; 22: 3023-3031.
24. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2009; 26: 2013-2019.